These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 34370268)

  • 1. STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.
    Wang Q; Lu B; Zhang Y; Yu J; Guo J; Zhou Q; Lv H; Sun Y
    Hum Cell; 2021 Nov; 34(6):1855-1865. PubMed ID: 34370268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers.
    Chang YF; Lim KH; Chiang YW; Sie ZL; Chang J; Ho AS; Cheng CC
    BMC Cancer; 2019 Oct; 19(1):959. PubMed ID: 31619200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
    Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
    J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
    Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
    Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
    Peng C; Li P; Yang M; Chen D; Huang Y
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):538-547. PubMed ID: 34334155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer.
    Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH
    Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
    Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage-induced Expression of TonEBP/NFAT5 Is Associated With Gefitinib Resistance and Migration in PC-9 Cells.
    Song HJ; Sharma S; Kim T; Kim YH; Kim SJ; Kang MW; Lee SD
    Anticancer Res; 2024 Sep; 44(9):3867-3874. PubMed ID: 39197931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
    Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
    Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells.
    Cui Z; Liu Z; Zeng J; Zhang S; Chen L; Zhang G; Xu W; Song L; Guo X
    Life Sci; 2019 May; 224():23-32. PubMed ID: 30902544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells].
    Gong H; Yuan Y; Li Y; Zhang H; Li Y; Li W; Wang P; Shi R; Liu C; Cui L; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):255-263. PubMed ID: 31109434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of ghrelin receptor reverses gefitinib resistance in lung cancer.
    Li X; Zhao X; Li C; Liu S; Yan F; Teng Y; Feng J; Miao D
    Hum Cell; 2019 Jul; 32(3):360-366. PubMed ID: 31020605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.